Skip to main content

GLP-3 Peptide: Does It Exist & What Are People Actually Searching For?

Short answer: there is no drug, hormone, or receptor called GLP-3. The term is internet shorthand, and almost everyone typing it is looking for a newer multi-receptor agonist, usually retatrutide. This guide explains where the "GLP-3" label came from, what the real incretin peptide family looks like, and which medication you probably want.

Does a GLP-3 Peptide Actually Exist?

No. There is no peptide hormone named glucagon-like peptide-3, no GLP-3 receptor, and no medicine approved or in trials under that name. The naming looks like it should follow GLP-1 and GLP-2, but biology does not work that way. GLP-1 and GLP-2 are two distinct products of the same precursor gene, proglucagon. There is no third numbered member of that series.

So when a product or forum post references a "GLP-3 peptide," it is using a nickname, not a scientific term. The real target of nearly all these searches is a triple receptor agonist, and the most prominent one is retatrutide.

Where the "GLP-3" Term Came From

The label spread through a simple counting habit. Semaglutide activates one receptor pathway (GLP-1). Tirzepatide activates two (GLP-1 and GIP). Retatrutide activates three (GLP-1, GIP, and glucagon). People started numbering the generations: first-gen GLP-1, second-gen "GLP-2" for tirzepatide, third-gen "GLP-3" for retatrutide.

It is memorable, but it collides with real terminology. GLP-2 is already a distinct gut hormone that regulates intestinal growth, unrelated to weight-loss drugs. And tirzepatide is a GLP-1/GIP agonist, not a "GLP-2 drug." The shorthand confuses more than it clarifies, which is exactly why this page exists.

The Real Incretin & Proglucagon Peptide Family

The hormones that matter for metabolic drugs are GLP-1, GIP, and glucagon, plus amylin as a related target. Here is what each one actually does:

  • GLP-1: boosts insulin after meals, slows gastric emptying, and reduces appetite. The target of semaglutide and liraglutide.
  • GIP: a second incretin that adds insulin sensitivity and appetite effects. Tirzepatide adds GIP on top of GLP-1.
  • Glucagon: raises energy expenditure and mobilizes stored fat. Retatrutide adds glucagon activity to drive larger weight loss.
  • GLP-2: promotes intestinal lining growth. Real, but not a weight-loss target and not what "GLP-2 drug" usually means online.
  • Amylin: a separate satiety hormone. Cagrilintide is an amylin analog used with semaglutide.

For a fuller map of the drugs built on these hormones, see our complete list of GLP-1 medications and the GLP-1 complete guide.

Retatrutide: The Drug People Usually Mean

Retatrutide is Eli Lilly's investigational triple agonist, hitting GLP-1, GIP, and glucagon receptors. That third target, glucagon, is what separates it from tirzepatide and drives its unusually large weight-loss numbers. In the Phase 3 TRIUMPH-1 trial reported in 2026, participants lost roughly 28% of body weight on average at 80 weeks, the highest figure published for this class so far.

If "GLP-3" brought you here, retatrutide is almost certainly the drug you were looking for. Dig into the details in our guides on how retatrutide works, its side effects, weight-loss results, and expected cost.

Triple vs Dual vs Single Agonists

The generational framing people compress into "GLP-1, GLP-2, GLP-3" is really about how many receptors a drug engages:

  • Single (GLP-1): semaglutide, liraglutide. Around 15% average weight loss for semaglutide in STEP 1.
  • Dual (GLP-1/GIP): tirzepatide. Up to about 22.5% in SURMOUNT-1. Compare the two in retatrutide vs tirzepatide.
  • Triple (GLP-1/GIP/glucagon): retatrutide. Roughly 28% in TRIUMPH-1.

More receptors has meant more weight loss on average, but also a different side-effect and safety picture, and only the single and dual agonists are FDA-approved today.

GLP-3 vs GLP-1: What the Nickname Misses

GLP-1 is a genuine hormone with decades of research behind it. The informal "GLP-3" is not a hormone at all, so comparing them like two versions of the same thing is misleading. A cleaner way to think about it: GLP-1 drugs pull one metabolic lever, while retatrutide (the "GLP-3" stand-in) pulls three at once.

If your real question is which approved option fits you, start with GLP-1 for weight loss and peptides for weight loss, since retatrutide is not yet on the market.

Other Next-Generation GLP Peptides

Retatrutide is not the only drug in the "next-gen GLP" conversation. Others people conflate with a mythical GLP-3 include:

None is a "GLP-3," but together they cover most of what people mean by the newest wave of GLP drugs.

Availability & Legal Status

Retatrutide, the drug behind the "GLP-3" searches, is not FDA-approved and is not legally available by prescription as of 2026. Eli Lilly is expected to file for approval after its remaining Phase 3 trials read out, with a possible market launch in the 2027-2028 window. See retatrutide availability for the current status.

By contrast, semaglutide and tirzepatide are approved and can be prescribed. If you want a legal option now, those are the real choices, not anything sold as "GLP-3."

Should You Buy Anything Sold as "GLP-3"?

No. Products marketed as "GLP-3 peptide" or gray-market "retatrutide for sale" are unregulated research chemicals. There is no guarantee the vial contains what the label claims, at the stated purity or dose, and dosing errors with potent metabolic peptides can be dangerous. The FDA has flagged fraudulent and mislabeled compounded GLP-1 products, and an unapproved triple agonist bought online carries even less oversight.

The safer path is a licensed provider and an approved medication. Learn what separates legitimate sources from research-chem vendors in what are peptides.

Frequently Asked Questions About GLP-3 Peptide

No. There is no hormone, receptor, or approved drug named GLP-3. The incretin and related peptide family includes GLP-1 (glucagon-like peptide-1), GLP-2, GIP, and glucagon. When people search for "GLP-3 peptide" they are almost always looking for a next-generation multi-receptor agonist, most often retatrutide, which acts on three receptors at once. The "GLP-3" label is informal shorthand that stuck online, not a real biochemical class.

Retatrutide. It is Eli Lilly's investigational triple agonist that activates GLP-1, GIP, and glucagon receptors. Because it hits one more target than tirzepatide (a dual GLP-1/GIP agonist), some people call it a "third-generation GLP" or loosely "GLP-3." In Phase 3 TRIUMPH-1 data reported in 2026, retatrutide produced roughly 28% average body weight loss at 80 weeks, the highest figure yet for this drug class.

Functionally, when someone says "GLP-3" they usually mean retatrutide, but the name is not accurate. Retatrutide is a triple receptor agonist, not a "GLP-3 receptor" agonist, because no GLP-3 receptor exists. The mislabeling comes from a loose counting logic: semaglutide targets one pathway, tirzepatide two, retatrutide three, so people number them GLP-1, GLP-2, GLP-3. That numbering does not match the real receptor biology.

No legitimate product is sold as "GLP-3." Retatrutide, the drug the term usually refers to, is not FDA-approved and is not available by prescription as of 2026. Anything marketed online as "GLP-3 peptide" or "retatrutide for sale" is an unregulated research chemical of unverified identity, purity, and dose. These are not quality-controlled medicines and carry real safety and legal risk.

GLP-1 is a real gut hormone and the target of drugs like semaglutide (Ozempic, Wegovy). The informal "GLP-3" is not a real hormone at all; it is a nickname for triple agonists like retatrutide that add GIP and glucagon activity on top of GLP-1. So the practical difference is the number of receptors engaged: one for GLP-1 drugs, three for the "GLP-3" shorthand.

Retatrutide has produced larger average weight loss than tirzepatide in trials, but it is still investigational and its full long-term safety profile is not established. Tirzepatide is FDA-approved and has years of post-market data. Stronger weight loss does not automatically mean better for a given person, and the added glucagon activity changes the side effect and metabolic picture. Neither should be used without medical supervision.

Yes. The pipeline includes survodutide (GLP-1/glucagon dual agonist), mazdutide (GLP-1/glucagon), cagrilintide (an amylin analog often paired with semaglutide as CagriSema), and orforglipron (an oral small-molecule GLP-1). None of these is a "GLP-3," but they are the real drugs behind most next-generation GLP searches.